Login to Your Account



Search

Search results

Clinic roundup

Vernalis plc , of Winnersh, U.K., reported the results from a phase Ib/II proof-of-concept study of V81444, an A2A antagonist which has potential applications for the treatment of Parkinson's disease, attention deficit hyperactivity disorder (ADHD) a ...

BioWorld Today - Staff - 2014-04-25 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Baxter International Inc. , of Deerfield, Ill., said it started dosing patients with malignant solid tumors in a Phase I study of a fully human recombinant anti-macrophage migration inhibitory factor (MIF) monoclonal antibody. (BioWo ...

BioWorld Today - Staff - 2012-09-06 00:00 - 0 comments - 0 attachments

Clinic Roundup

• Cel-Sci Corp. , of Vienna, Va., said a second interim review of the safety data from its open-label, randomized, Phase III study of immunotherapy candidate Multikine (leukocyte interleukin, injection) was conducted, with the independent data monito ...

BioWorld Today - Staff - 2013-11-06 01:00 - 0 comments - 0 attachments

Clinic roundup

Alder Biopharmaceuticals Inc. , of Bothell, Wash., said researchers will present findings from a randomized, double-blind, placebo-controlled proof-of-concept trial of lead compound ALD403 in preventing frequent episodic migraine at the American Acad ...

BioWorld Today - Staff - 2014-04-24 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Eisai Co. Ltd. , of Tokyo, reported that Zonegran (zonisamide) was well tolerated and efficacious when used as an adjunctive treatment for partial epilepsy, with or without secondary generalization, in children between the ages of 6 and 17 for at lea ...

BioWorld Today - Staff - 2014-04-23 00:00 - 0 comments - 0 attachments

Clinic roundup

Nitto Denko Corp. , of Osaka, Japan, said dosing of healthy volunteers in a phase I study has completed for an RNAi-based drug aimed at treating fibrosis in the liver and other organs, and the company is advancing the drug to a phase I/II study in pa ...

BioWorld Today - Staff - 2014-04-23 00:00 - 0 comments - 0 attachments

Clinic roundup

Questcor Pharmaceuticals Inc. , of Anaheim Hills, Calif., said that results from an investigator-initiated clinical study showed that H.P. Acthar Gel (repository corticotropin) could be a potentially useful therapy for inducing remission of proteinur ...

BioWorld Today - Staff - 2014-04-22 00:00 - 0 comments - 0 attachments

Clinic roundup

Stemcells Inc. , of Newark, Calif., completed enrollment of the phase I/II trial in spinal cord injury, testing the safety and preliminary efficacy of the HuCNS-SC human neural stem cells. The trial enrolled 12 subjects with chest-level injury to t ...

BioWorld Today - Staff - 2014-04-18 00:00 - 0 comments - 0 attachments

Clinic roundup

Cleveland Biolabs Inc. , of Buffalo, New York, said it successfully evaluated CBL0102 (quinacrine), an orally administered small molecule, for maximum tolerated dose and dose-limiting toxicities in patients with advanced cancers during a phase I tria ...

BioWorld Today - Staff - 2014-04-17 00:00 - 0 comments - 0 attachments

Clinic roundup

Akebia Therapeutics Inc. , of Cambridge, Mass., said it completed enrollment in its ongoing 200-patient phase IIb study of AKB-6548, a hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia associated with chronic kidney d ...

BioWorld Today - Staff - 2014-04-16 00:00 - 0 comments - 0 attachments